Loading…
Loading…
SZLSF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SZLSF and 80,000+ other tickers.
See exactly how SZLSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SZLSF and 80,000+ other tickers.
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada. At the core of their offerings is the proprietary Sentinel Principle platform technology, which specializes in identifying novel biomarkers from whole blood samples. The company's lead product, Aristotle, is an…
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Envista (NYSE: NVST - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings This table compares Stagezero Life
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Fonar (NASDAQ: FONR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 50.6% of Fonar
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Insulet (NASDAQ: PODD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Earnings and Valuation This table compares Stagezero Life
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Valuation and Earnings This table
TORONTO, ON - TheNewswire - May 13, 202 5 - StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (" StageZero " or the " Company "), and ElevationMD ( “ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer. StageZero is an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and AVRT, an oncologist-led metabolic screening and treatment protocol for detecting the early warning signs of cancer and chronic disease, together with ElevationMD today announced they are introducing state of the art early cancer screening to ElevationMD's patients in British Columbia.